Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CURO Group Holdings Corp. stock logo
CURO
CURO Group
$0.04
$0.04
$0.04
$2.25
$1.69M2.21984,281 shsN/A
Magic Empire Global Limited stock logo
MEGL
Magic Empire Global
$1.61
-5.8%
$1.36
$1.02
$5.52
$6.54M2.661.31 million shs312,571 shs
Netcapital Inc. stock logo
NCPL
Netcapital
$2.66
+7.7%
$2.09
$1.41
$11.90
$5.83M-0.13240,118 shs312,951 shs
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
$0.73
-2.4%
$0.84
$2.08
$5.30
$6.31M-0.2651,388 shs674,576 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CURO Group Holdings Corp. stock logo
CURO
CURO Group
0.00%0.00%0.00%0.00%-25.45%
Magic Empire Global Limited stock logo
MEGL
Magic Empire Global
0.00%+28.80%+10.45%+10.27%-30.87%
Netcapital Inc. stock logo
NCPL
Netcapital
0.00%-0.75%+31.03%+40.00%-66.81%
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
-2.39%+5.76%+9.76%-50.53%-80.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CURO Group Holdings Corp. stock logo
CURO
CURO Group
N/AN/AN/AN/AN/AN/AN/AN/A
Magic Empire Global Limited stock logo
MEGL
Magic Empire Global
1.8128 of 5 stars
0.05.00.00.03.31.70.6
Netcapital Inc. stock logo
NCPL
Netcapital
1.0164 of 5 stars
0.05.00.00.02.60.00.6
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CURO Group Holdings Corp. stock logo
CURO
CURO Group
0.00
N/AN/AN/A
Magic Empire Global Limited stock logo
MEGL
Magic Empire Global
0.00
N/AN/AN/A
Netcapital Inc. stock logo
NCPL
Netcapital
0.00
N/AN/AN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CURO Group Holdings Corp. stock logo
CURO
CURO Group
$418.33M0.00$2.05 per share0.02($1.34) per share-0.03
Magic Empire Global Limited stock logo
MEGL
Magic Empire Global
$12.78M0.51N/AN/A$3.39 per share0.47
Netcapital Inc. stock logo
NCPL
Netcapital
$812.61K7.18N/AN/A$115.96 per share0.02
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/A$1.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CURO Group Holdings Corp. stock logo
CURO
CURO Group
-$266.73M-$6.49N/AN/AN/A-35.34%N/A-8.23%N/A
Magic Empire Global Limited stock logo
MEGL
Magic Empire Global
-$60KN/A0.00N/AN/AN/AN/AN/A
Netcapital Inc. stock logo
NCPL
Netcapital
-$4.99M-$20.20N/A1.90N/A-562.71%-25.03%-22.67%8/4/2025 (Estimated)
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/12/2025 (Estimated)

Latest CURO, NRBO, MEGL, and NCPL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/17/2025Q3 2025
Netcapital Inc. stock logo
NCPL
Netcapital
-$0.70-$1.57-$0.87-$1.57$1.13 million$0.15 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CURO Group Holdings Corp. stock logo
CURO
CURO Group
$0.441,073.17%N/AN/A N/A
Magic Empire Global Limited stock logo
MEGL
Magic Empire Global
N/AN/AN/AN/AN/A
Netcapital Inc. stock logo
NCPL
Netcapital
N/AN/AN/AN/AN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CURO Group Holdings Corp. stock logo
CURO
CURO Group
N/A
9.33
9.33
Magic Empire Global Limited stock logo
MEGL
Magic Empire Global
N/A
56.75
N/A
Netcapital Inc. stock logo
NCPL
Netcapital
N/A
0.35
0.35
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/A
2.41
2.41

Institutional Ownership

CompanyInstitutional Ownership
CURO Group Holdings Corp. stock logo
CURO
CURO Group
39.87%
Magic Empire Global Limited stock logo
MEGL
Magic Empire Global
0.51%
Netcapital Inc. stock logo
NCPL
Netcapital
30.69%
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
1.37%

Insider Ownership

CompanyInsider Ownership
CURO Group Holdings Corp. stock logo
CURO
CURO Group
26.12%
Magic Empire Global Limited stock logo
MEGL
Magic Empire Global
63.02%
Netcapital Inc. stock logo
NCPL
Netcapital
6.77%
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
1.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
CURO Group Holdings Corp. stock logo
CURO
CURO Group
5,20041.30 million30.51 millionOptionable
Magic Empire Global Limited stock logo
MEGL
Magic Empire Global
84.06 million1.50 millionNot Optionable
Netcapital Inc. stock logo
NCPL
Netcapital
N/A2.19 million1.72 millionNot Optionable
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
108.62 million8.53 millionNot Optionable

Recent News About These Companies

NeuroBo Pharmaceuticals rebrands to become MetaVia
NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes
NeuroBo Pharmaceuticals announces relignment, change name

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURO Group stock logo

CURO Group NYSE:CURO

CURO Group Holdings Corp., together with its subsidiaries, provides consumer finance products in the United States and Canada. The company offers secured and unsecured installment loans, revolving line of credit, and single-pay loans; and credit protection insurance, check cashing, money transfer, foreign currency exchange, and other ancillary financial products and services, as well as reloadable prepaid debit cards and demand deposit accounts. The company also provides loans through online. It operates under the Covington Credit, Heights Finance, Quick Credit, Southern Finance, First Heritage Credit, Cash Money, LendDirect, and Flexiti brands. The company was formerly known as Speedy Group Holdings Corp. and changed its name to CURO Group Holdings Corp. in May 2016. CURO Group Holdings Corp. was founded in 1997 and is headquartered in Chicago, Illinois.

Magic Empire Global stock logo

Magic Empire Global NASDAQ:MEGL

$1.61 -0.10 (-5.85%)
As of 06/13/2025 04:00 PM Eastern

Magic Empire Global Limited engages in the provision of corporate finance advisory services and underwriting services in Hong Kong. The company provides initial public offering sponsorship, financial and independent financial advisory, post-listing compliance advisory, and underwriting services by acting as global coordinator, bookrunner, lead manager, or underwriter. It also offers corporate services, which include accounting and financial reporting advisory, company secretarial services, internal control enhancement, investor relations advisory, and other consulting services. The company was incorporated in 2016 and is headquartered in Central, Hong Kong.

Netcapital stock logo

Netcapital NASDAQ:NCPL

$2.66 +0.19 (+7.69%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$2.72 +0.06 (+2.41%)
As of 06/13/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Netcapital Inc. operates as a fintech company. It offers Netcapital.com, an SEC-registered funding portal that enables private companies to raise capital online, as well as allows investors to invest from anywhere in the world. The company also provides various services, including automated onboarding process and filing of required regulatory documents; compliance review; custom-built offering page on its portal website; third party transfer agent and custodial services; and rolling closes which provides access to liquidity before final close date of offerings, as well as assistance with annual fillings and direct access to team for ongoing support. In addition, it offers advisor services, which includes incubation of technology start-ups; investors introduction; online marketing; website design and software development; message crafting including pitch decks, offering pages, and ad creation; strategic advice; and technology consulting services. Further, the company provides valuation services, such as business valuation, fairness and solvency opinions, ESOP feasibility and valuation, non-cash charitable contribution, economic analysis of damages, intellectual property appraisals, and compensation studies. Netcapital Inc. is based in Boston, Massachusetts.

NeuroBo Pharmaceuticals stock logo

NeuroBo Pharmaceuticals NASDAQ:NRBO

$0.73 -0.02 (-2.39%)
As of 06/13/2025

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.